Search results for "Opioid use disorder"
Warning about hand sanitizer; labeling changes for opioids
This column reviews details on recent recalls, warnings, and approvals.
https://immattersacp.org/archives/2020/09/warning-about-hand-sanitizer-labeling-changes-for-opioids.htm
1 Sep 2020
One-third of primary care physicians do not support medications for opioid use disorder
Fewer than a quarter of surveyed primary care physicians expressed interest in treating patients with opioid use disorder, and only 11.8% were interested in obtaining a waiver to prescribe buprenorphine.
https://immattersacp.org/weekly/archives/2020/04/21/2.htm
21 Apr 2020
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://immattersacp.org/archives/2019/09/latest-updates-on-acps-priorities-initiatives.htm
1 Sep 2019
USPSTF recommends primary care screening for illicit drug use in all adults
Public input on the draft recommendation from the U.S. Preventive Services Task Force (USPSTF) will be accepted until Sept. 9.
https://immattersacp.org/weekly/archives/2019/08/20/2.htm
20 Aug 2019
ACP supports proposed changes in Medicare payments to physicians
The new provisions were included in the proposed Medicare Physician Fee Schedule for 2020 that was released by CMS on July 29.
https://immattersacp.org/weekly/archives/2019/08/06/2.htm
6 Aug 2019
Fatal overdoses may be declining in the U.S.
The number of drug overdose deaths in the U.S. appears to have dropped from 2017 to 2018, according to the latest CDC estimates, although counts have not been finalized.
https://immattersacp.org/weekly/archives/2019/07/23/5.htm
23 Jul 2019
Access to buprenorphine assessed by ‘secret shopper’ study
More than third of simulated patients who portrayed themselves as heroin users seeking treatment were unable to get an appointment with a buprenorphine prescriber, and access was even lower among those reporting Medicaid coverage.
https://immattersacp.org/weekly/archives/2019/06/04/1.htm
4 Jun 2019
More recalls, information on impurity found in ARBs
This column reviews details on recent recalls, warnings, and approvals.
https://immattersacp.org/archives/2019/01/more-recalls-information-on-impurity-found-in-arbs.htm
1 Jan 2019
Daily medication appears more cost-effective than monthly injections for opioid use disorder
Over 24 weeks, extended-release naltrexone cost an average of $5,317 more than buprenorphine-naloxone, primarily because the former was more expensive and required a longer detoxification period.
https://immattersacp.org/weekly/archives/2018/12/18/1.htm
18 Dec 2018
Controlled substance agreements may reduce primary care visits, amid a decades-old, growing opioid crisis
Researchers retrospectively evaluated health care utilization changes among primary care patients receiving long-term opioid therapy for chronic noncancer pain who enrolled in a controlled substance agreement.
https://immattersacp.org/weekly/archives/2018/09/25/2.htm
25 Sep 2018